Greenstone launches rifabutin capsules

PEAPACK, N.J. — Greenstone, a U.S.-based generic pharmaceutical subsidiary of Pfizer, announced the introduction of rifabutin capsules to its product line. The capsules are offered in the dosage strength of 150-mg x 100.



The drug is the authorized generic version of Mycobutin and is used for the prevention of disseminated mycobacterium avium complex disease in patients with advanced HIV infection.